# OnCo record disco-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/disco-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "disco-pharmaceuticals" ;
  schema:name "DISCO Pharmaceuticals"@en ;
  schema:alternateName "DISCO Pharma"@en ;
  schema:description "DISCO Pharmaceuticals maps the proteins on the surface of cancer cells to find new targets, then turns them into antibody-drug conjugates and immune-cell engagers. Its first programmes are in small cell lung cancer and a common form of bowel cancer that does not respond to immunotherapy."@en ;
  schema:url <https://onco.cc/companies/disco-pharmaceuticals/>, <https://discopharma.de/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://discopharma.de/>, <https://discopharma.de/disco-pharmaceuticals-appoints-mark-manfredi-as-ceo-and-announces-final-close-of-e36-million-seed-financing/>, <https://discopharma.de/disco-pharmaceuticals-enters-license-agreement-to-advance-novel-cancer-surfaceome-targeted-therapies/>, <https://www.insideprecisionmedicine.com/topics/oncology/before-the-hype-five-early-stage-adc-startups-to-watch/> ;
  schema:addressCountry "DE" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/t-cell-engager/> .